Faricimab versus the standard of care for neovascular age-related macular degeneration in Italy: an indirect treatment comparison
Objectives: To assess through an indirect treatment comparison (ITC) the potential benefit of faricimab over the anti-vascular endothelial growth factor (VEGF) real-life scenario, hereby defined standard of care (SoC), in Italy, that is, aflibercept, bevacizumab, and ranibizumab, in patients with ne...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AboutScience Srl
2024-12-01
|
| Series: | Drug Target Insights |
| Subjects: | |
| Online Access: | https://journals.aboutscience.eu/index.php/dti/article/view/3213 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!